Dab hand at finances


Dab hand at finances

04.08.2016 - US- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.

Shannon, who holds a Bachelor of Business Administration from Appalachian State University, also worked at Talecris Biotherapeutics, Inc., Harris Wholesale, Inc. and PricewaterhouseCoopers LLP. He will be based out of of Inivata’s US Research Triangle Park office with global responsibilities for Inivata’s financial and operational management.


02.08.2016 Philippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.

© NeMoDevices

Philippe Dro previously served as CEO of GlycoVaxyn AG, a Swiss biotech startup in vaccines, which was acquired by GSK in early 2015. Before GlycoVaxyn, Dro was CEO of EndoArt SA, a medical technology company spin-out from the École polytechnique fédérale de Lausanne (EPFL), which was acquired by Allergan in early 2007. Dro holds a PhD in pharmacy from the University of Grenoble as well as an MBA  from Ecole Superieure de Commerce de Lyon and Cranfield School of Management in the United Kingdom.


29.07.2016 UK diagnostics company Arquer Diagnostics Ltd has appointed Louise Flintoft as product mananger. Flintoft will be responsible for product marketing of Arquer's Mcm5-ELISA test, a urine test for bladder cancer.

© Arquer

Louise Flintoft has over ten years of sales and marketing experience in the biotech and companion diagnostic industries. She has worked at Leica Biosystems, Vision BioSystems and Novacastra Laboratories. Flintoft completed a Batchelor’s Degree with Honours in Physiology at the University of Newcastle.​


25.07.2016 Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.

© Wilson Therapeutics

Lilley, who received his BSc in microbiology and genetics as well as his PhD in molecular genetics from Queen Mary College, University of London, has held senior positions in regulatory affairs and drug development in Europe, Japan and USA for the last three decades. Most recently, he served as Senior VP and Head of Global Regulatory Affairs at US pharma company Vertex Pharmaceuticals. At Vertex, he was responsible for the global filings for the breakthrough orphan drug Orkambi. Prior to that, Lilley was VP and Head of Global Regulatory Affairs at Belgian biopharma UCB. He has also held senior regulatory positions at Johnson & Johnson, Shire and AstraZeneca. 


20.07.2016 Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.


EBE, the European trade association that represents European biopharmaceutical companies of all sizes, appointed Bravo in June. He had already served as Vice President of EBE for some time.

Bravo, who holds a degree in Business Administration and an MBA (INSEAD), has been CEO of TiGenix since May 2011. He joined the Belgian company in 2005. Prior to that, he held several senior management positions at Sanofi-Aventis, including Vice President for Latin America. He was also general manager for Belgium. Prior to his tenure at Sanofi-Aventis, Bravo spent seven years at SmithKline Beecham in commercial positions both nationally and internationally. 


18.07.2016 Uwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx’ lead candidate MIN-102 for adrenoleukodystrophy.

© Minoryx

Meya, a neurologist and psychiatrist, joins Minoryx Therapeutics from Swiss Lupin Atlantis Holdings SA, where he was responsible for clinical strategy and implementation of studies with new clinical entities in various indications, including neurodegenerative disorders. 

Previously, he worked at Synosia Therapeutics, Roche and Novartis. Meya received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.


13.07.2016 In July, British research service provider Envigo appointed Adrian Hardy as President and CEO. Hardy will also join Envigo’s Board of Directors.

© Envigo

Hardy, who holds a BSc in Human Biology from King’s College London and a PhD in Developmental Biology from University College London, has been with Envigo since 2002. He held various roles in Sales, Strategic Marketing and Operations. Most recently, Hardy held the position of COO. 


11.07.2016 US-Dutch medical device company EndoStim, developer of neurostimulation therapy for gastroesophageal reflux disease, has named ­Rohan Hoare as president and CEO. He succeeds founder Bevil Hogg, who will continue to serve the company as a consultant.

© EndoStim

Hoare, who holds a Master of Arts and a PhD in physics from Harvard University, was previously president of the Neuromodulation business unit of Livanova, the London-based company formed by the merger of Cyberonics and Sorin Group.


06.07.2016 Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the company’s helm for good. Kymab’s new old CEO is stepping down from his role as Chairman, however.

© Kymab

Chiswell was one of the co-founders of Cambridge Antibody Technology (CAT), where he also served as CEO from 1996 till 2002. Chiswell currently serves as chairman of Albireo Pharma, Swedish developer of treatments for gastrointestinal disease, and is a director of Austria’s antibiotics specialist Nabriva Therapeutics. He is also a former chairman of the UK BioIndustry association (BIA). In 2006, he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.


04.07.2016 The EMA’s Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, is the Veterinary Assessment Manager at the Health Products Regulatory Authority in Ireland.


Murphy has been a CVMP member since 2009 and has served as Vice-Chair and Chair of the Strategic Planning Group. He holds a PhD from the University of Glasgow in Equine Medicine. 

The mandate covers three years starting in June 2016. The CVMP will elect a new Vice-chair in July.


01.07.2016 Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.

© Promethera

Hombeck was Co-CEO and Chief Business Officer at Cytonet GmbH & Co KG, spokesperson, Co-CEO and Chief Financial Officer at Agennix AG and Chief Financial officer at GPC Biotech AG. He has extensive experience in clinical and commercial drug development, as well as with regulatory filings for various drug development product candidates and financings of private and public companies including IPOs and follow ons. He received an MBA and Ph.D. in finance from the European Business School University of Business and Law in Oestrich-Winkel, Germany.

Promethera also appointed Christof Hettich as new Chairman of the Board. 

1/37Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • RENEURON (UK)2.88 GBP4.73%
  • SUMMIT (UK)4.03 GBP3.87%


  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%


  • DIAMYD MEDICAL -B- (S)6.90 SEK47.1%
  • KARO BIO (S)42.00 SEK34.6%


  • BIONOR PHARMA (N)0.44 NOK-25.4%
  • E-THERAPEUTICS (UK)11.50 GBP-14.8%
  • ZEALAND PHARMA (DK)112.00 DKK-14.5%


  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%
  • GENMAB (DK)1094.00 DKK85.0%


  • BB BIOTECH (D)44.29 EUR-83.1%
  • EVOCUTIS (UK)0.04 GBP-77.8%

No liability assumed, Date: 27.08.2016


All Events